Velorum Therapeutics

Executive Summary

Velorum Therapeutics is a U.S.-based preclinical biotech developing novel biologics that target heme and porphyrin pathways. Leveraging proprietary porphyrin-scavenging and heme-sequestering proteins, the company aims to treat rare porphyrias, heme-driven cancers, and organ injury from excess free heme. Founded in 2020 and headquartered in South San Francisco, Velorum operates in the oncology, hematology, and kidney disease spaces. The company's platform addresses a unique biological niche—heme metabolism—which has implications across multiple disease areas. Currently in preclinical stage, Velorum's lead programs are focused on erythropoietic protoporphyria (EPP) and acute intermittent porphyria (AIP), with potential expansion into solid tumors where heme availability drives tumor growth. The company’s scientific foundation is supported by publications from its founders and key opinion leaders in porphyrin biology. Despite being early-stage, Velorum's approach has attracted interest from rare disease investors and potential partners given the high unmet need and orphan drug potential. The company remains private with no disclosed funding, but its target indications offer clear regulatory pathways and commercial incentives.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement70% success
• Q2 2027IND Filing for Lead Program in Erythropoietic Protoporphyria50% success
• Q1 2027Preclinical Proof-of-Concept Data in a Heme-Driven Cancer Model60% success